PT-141 (bremelanotide): Vyleesi, FDA status and prescription

What is PT-141 and how does it work?

PT-141, PT141, peptide 141 and bremelanotide are names for the same molecule. The label calls it "a melanocortin receptor (MCR) agonist that nonselectively activates several receptor subtypes" (DailyMed). Put simply, it switches on a group of receptors in the body, including ones in the brain linked to desire. The label also says the way it helps low desire is unknown.

That makes it different from drugs such as sildenafil (Viagra), which work on blood flow. PT-141 is aimed at desire, not at the mechanics of an erection.

Vyleesi is "self-administered via a prefilled autoinjector pen" under the skin, and the label tells patients to use it as needed before sex. We do not publish how much or how often; that is for the prescriber.

PT-141 side effects

The Vyleesi label lists the side effects found in its trials. We read it on 9 Nov 2026.

What the label says	In plain words
"Most common adverse reactions (incidence > 4%) are nausea, flushing, injection site reactions, headache, and vomiting."	These were the most common problems in the trials
Nausea was "reported in 40% of VYLEESI-treated patients"	About 4 in 10 people had nausea
"VYLEESI transiently increases blood pressure and reduces heart rate after each dose."	Blood pressure goes up for a while after each shot
"Consider discontinuing VYLEESI if hyperpigmentation develops."	Dark patches can appear on the skin
Do not use with "uncontrolled hypertension or known cardiovascular disease"	People with high blood pressure that is not controlled, or heart disease, should not use it

These facts come from the approved product. A compounded product has no label of its own, so its side effects have not been studied in the same way.

FDA status of PT-141, checked 9 Nov 2026

Form	Status on the sources we read	Source
Vyleesi (bremelanotide) injection	FDA-approved for one labeled use	DailyMed: Vyleesi label
Compounded bremelanotide (sold as PT-141)	Not FDA-approved. Not one of the six peptides in the HHS interim policy	Federal Register 2026-22192

The Vyleesi label says it is "indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)" (DailyMed). It also says Vyleesi is "not indicated for the treatment of HSDD in postmenopausal women or in men" and "not indicated to enhance sexual performance". We read the label on 9 Nov 2026.

HHS's policy of 28 October 2026 covers six peptides: BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV. Bremelanotide is not one of them. That policy is interim, and compounded drugs are not FDA-approved. The dated record is in the peptide legal status tracker, and the policy itself is explained in the HHS peptide policy.

Can a pharmacy compound bremelanotide?

Under section 503A, a pharmacy may compound from bulk drug substances that are "components of drugs approved by the Secretary" when no USP monograph exists. Bremelanotide is the active ingredient of an approved drug. The same law says a pharmacy must not compound "regularly or in inordinate amounts" drug products "that are essentially copies of a commercially available drug product."

We are not lawyers and make no ruling on any pharmacy. In practice, a compounded product is a different thing from Vyleesi, which FDA reviewed for safety and effectiveness. If a program offers "PT-141", ask which pharmacy compounds it and why a prescriber chose it over the approved product.

What a prescription program does

A licensed clinician reviews your history, and a state-licensed pharmacy fills the prescription. That is the route this site covers. It is different from vials labeled for research use, which have no clinician and no prescription; see research vs prescription peptides.

PT-141 for men: what the label says

Many searches for PT-141 come from men. The Vyleesi label is plain: it is "not indicated for the treatment of HSDD in postmenopausal women or in men." The approved trials were in premenopausal women with HSDD, which stands for hypoactive sexual desire disorder, a diagnosis of low desire that causes distress. We found no FDA label or HHS document supporting compounded bremelanotide for men or for performance, so we make no claim about either. A man asking about PT-141 should ask a prescriber about approved options first.

What to check before you pay

• Which product is it? Ask whether you are getting Vyleesi or a compounded product. They are not the same.
• Is a clinician involved? A licensed prescriber should review your history first.
• Is the pharmacy named? A program that names its 503A pharmacy is easier to hold to account.
• What does the label say about you? The approved label is for a narrow group. Ask your prescriber how your case fits.
• How is it billed? Check plan length, shipping and visit fees on the program's own page.

FAQ

PT-141 prescription: can I get it online?

Some telehealth programs offer it after a clinician review, but none of the programs we track publishes a PT-141 price. The approved product is Vyleesi, and compounded versions are not FDA-approved. Ask the program which product you would receive. See best peptide programs.

Is PT-141 FDA-approved?

Bremelanotide is FDA-approved only as Vyleesi, for premenopausal women with acquired, generalized HSDD. A compounded "PT-141" is not FDA-approved. It is also not among the six peptides in HHS's interim policy of 28 October 2026.

What is the difference between PT-141 and Vyleesi?

Vyleesi is the FDA-approved brand of bremelanotide, made and labeled by its manufacturer. "PT-141" is the name used for the same molecule in compounded products and elsewhere. A compounded product has not been reviewed by FDA for safety and effectiveness.

What is PT-141 nasal spray versus injection?

Vyleesi is an injection. We found no FDA or HHS document covering a compounded nasal bremelanotide product, so we make no claim about one. If a program offers a nasal form, ask which pharmacy compounds it and on what authority.

What are the side effects of PT-141?

The Vyleesi label lists nausea, flushing, injection site reactions, headache and vomiting as the most common. Nausea affected about 4 in 10 people in the trials. The label also warns of a short rise in blood pressure after each dose and dark skin patches. Compounded products have no label of their own.

Is PT-141 safe?

The approved form, Vyleesi, has an FDA label that lists its risks, and it should not be used by people with uncontrolled high blood pressure or heart disease. Compounded PT-141 has not been reviewed by FDA. Talk to a prescriber about your own history before using anything.

Does PT-141 work for men?

It is not approved for men. The Vyleesi label says it is not indicated in men or in postmenopausal women. We found no FDA or HHS document supporting compounded bremelanotide for men, so ask a prescriber about approved options instead.

Is PT-141 the same as peptide 141 or bremelanotide?

Yes. Bremelanotide, PT-141, PT141 and "peptide 141" name the same molecule. The status depends on the product: Vyleesi is approved, and compounded versions are not FDA-approved.

Compare every program on the price table, or see our ranked best peptide programs.